Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share (the “Shares”), to funds managed by Deerfield Management Company, L.P., which are existing investors in the Company, at a purchas

Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q4 2020 Results - Earnings Call Transcript

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates

CHICAGO--(BUSINESS WIRE)-- #T1D--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the fourth quarter and full-year 2020 and recent highlights. “Despite the obvious challenges of 2020, I believe it was a very successful year for Xeris, and in particular, the fourth quarter. We saw continuous growth

Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights

Xeris Pharmaceuticals (NASDAQ:XERS) unveils its next round of earnings this Tuesday, March 09. Get prepared with Benzinga's ultimate preview for Xeris Pharmaceuticals's Q4 earnings.

Earnings Outlook for Xeris Pharmaceuticals

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and full-year 2020 financial results before the open of the U.S. financial markets on Tuesday, March 9, 2021. Management will host a conference call and webcast at 8:30 a.m. ET that day to

Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the following upcoming investor conferences: SVB Leerink Annual Global Healthcare Conference: Friday, February 26, 2021 at 1

Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations

Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolio's closet and haven't paid attention despite it hitting new 52-week highs. The company recently received European approval for their premixed RTU liquid glucagon auto-injector for very low blood sugar.

Xeris: Recent Success Warrants A Closer Look

The stock price of Xeris Pharmaceuticals Inc (NASDAQ: XERS) is trading at over 20% pre-market. This is why it happened.

XERS Stock Price Increases Over 20% Pre-Market: Why It Happened

The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. Hypoglycemia (low blood sugar level) is a complication of glucose-lowering therapy.

Xeris Pharma's Hypoglycemia Med Receives European Nod, Shares Spike

CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation i

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals (XERS) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021. A webcast of the on-demand presentati

Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, for the commercialization in Israel and the Palestinian Authority of Xeris' Gvoke® (glucagon in

Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Do Options Traders Know Something About Xeris Pharmaceuticals (XERS) Stock We Don't?

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, announced that yesterday the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon). Ogluo is the EU trade name for Xeris' RTU glucagon for injection. The CHMP recommen

Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with potential, and George Soros recently purchased a 5% stake.

Xeris Pharmaceuticals: Marketed Product Company With Platform And Soros Investment Makes Me More Bullish

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) Reports Q3 Loss, Tops Revenue Estimates

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results.

Xeris Pharmaceuticals: Q3 Earnings Insights

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the third quarter and nine months ended September 30, 2020, as well as pipeline and corporate highlights. “The third quarter results showed the tremendous response from the diabetes community to the highly anti

Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its third quarter 2020 financial results before the open of the U.S. financial markets on Monday, November 9, 2020. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the C

Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it was granted Fast Track designation by the Food and Drug Administration (FDA) for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures. Xeris' XP-0863 was previously granted orphan designation

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R.

News for Xeris Biopharma Holdings Stock (XERS)